Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Long-Term Debt Repayments (2019 - 2020)

aTYR PHARMA (ATYR) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $3.1 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Long-Term Debt Repayments rose 54.15% year-over-year to $3.1 million, compared with a TTM value of $9.1 million through Dec 2020, up 13.54%, and an annual FY2020 reading of $9.1 million, up 13.54% over the prior year.
  • Long-Term Debt Repayments was $3.1 million for Q4 2020 at aTYR PHARMA, up from $2.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $3.1 million in Q4 2020 and bottomed at $2.0 million in Q1 2019.